{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:26:40Z","timestamp":1795080400902,"version":"4.10.2"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To examine the association between first-trimester angiotensin-converting enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central nervous system malformations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We used a cohort of completed pregnancies linked to liveborn neonates derived from Medicaid claims from 2000 to 2010. We examined the risk of malformations associated with first-trimester exposure to an ACE inhibitor. Propensity score\u2013based methods were used to control for potential confounders including maternal demographics, medical conditions, exposure to other medications, and measures of health care utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>The cohort included 1,333,624 pregnancies, of which 4,107 (0.31%) were exposed to ACE inhibitors during the first trimester. The prevalence of overall malformations in the ACE inhibitor\u2013exposed pregnancies was 5.9% compared with 3.3% in the unexposed (unadjusted relative risk, 1.82; 95% confidence interval [CI] 1.61\u20132.06), of cardiac malformations was 3.4% compared with 1.2% (relative risk 2.95, 95% CI 2.50\u20133.47), and of central nervous system malformations was 0.27% compared with 0.18% (relative risk 1.46, 95% CI 0.81\u20132.64). After restricting the cohort to pregnancies complicated by chronic hypertension (both exposed and unexposed) and accounting for other confounding factors, there was no significant increase in the risk of any of the outcomes assessed. Relative risks associated with first-trimester ACE inhibitor exposure were 0.89 (95% CI 0.75\u20131.06) for overall malformations, 0.95 (95% CI 0.75\u20131.21) for cardiac malformations, and 0.54 (95% CI 0.26\u20131.11) for CNS malformations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>After accounting for confounders, among women with hypertension, exposure to ACE inhibitors during the first trimester was not associated with an increased risk of major congenital malformations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000001775","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T08:59:24Z","timestamp":1481101164000},"page":"174-184","source":"Crossref","is-referenced-by-count":89,"title":["Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations"],"prefix":"10.1097","volume":"129","author":[{"given":"Brian T.","family":"Bateman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen W.","family":"Seely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Z.","family":"Dejene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hernandez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F.","family":"Huybrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"e36171","DOI":"10.1371\/journal.pone.0036171","article-title":"Hypertension in women of reproductive age in the United States: NHANES 1999\u20132008","volume":"7","author":"Bateman","year":"2012","journal-title":"PLoS One"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/pds.1550","article-title":"Outpatient use of cardiovascular drugs during pregnancy","volume":"17","author":"Andrade","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/HYPERTENSIONAHA.112.197095","article-title":"Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population","volume":"60","author":"Bateman","year":"2012","journal-title":"Hypertension"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/tera.1420440503","article-title":"ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection","volume":"44","author":"Barr","year":"1991","journal-title":"Teratology"},{"key":"R5-20230711","first-page":"128","article-title":"Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy","volume":"78","author":"Hanssens","year":"1991","journal-title":"Obstet Gynecol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1681\/ASN.V391575","article-title":"Angiotensin-converting enzyme inhibitor fetopathy","volume":"3","author":"Pryde","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors","volume":"354","author":"Cooper","year":"2006","journal-title":"N Engl J Med"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"d5931","DOI":"10.1136\/bmj.d5931","article-title":"Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study","volume":"343","author":"Li","year":"2011","journal-title":"BMJ"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/01443615.2011.579197","article-title":"Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers","volume":"31","author":"Walfisch","year":"2011","journal-title":"J Obstet Gynaecol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/bdra.23027","article-title":"Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence","volume":"94","author":"Polifka","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrcardio.2011.179","article-title":"Hypertension: ACE inhibitor use in pregnancy\u2014setting the record straight","volume":"9","author":"Koren","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/01.AOG.0000437382.03963.88","article-title":"Executive summary: hypertension in pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"e67405","DOI":"10.1371\/journal.pone.0067405","article-title":"Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations","volume":"8","author":"Palmsten","year":"2013","journal-title":"PLoS One"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/pds.3284","article-title":"Algorithms to estimate the beginning of pregnancy in administrative databases","volume":"22","author":"Margulis","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa1312828","article-title":"Antidepressant use in pregnancy and the risk of cardiac defects","volume":"370","author":"Huybrechts","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"h2102","DOI":"10.1136\/bmj.h2102","article-title":"Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study","volume":"350","author":"Desai","year":"2015","journal-title":"BMJ"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2015.5605","article-title":"Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn","volume":"313","author":"Huybrechts","year":"2015","journal-title":"JAMA"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/HYPERTENSIONAHA.111.00833","article-title":"The risk of congenital malformations associated with exposure to \u03b2-blockers early in pregnancy: a meta-analysis","volume":"62","author":"Yakoob","year":"2013","journal-title":"Hypertension"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/pds.3627","article-title":"Validity of maternal and infant outcomes within nationwide Medicaid data","volume":"23","author":"Palmsten","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3182a603bb","article-title":"Development of a comorbidity index for use in obstetric patients","volume":"122","author":"Bateman","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/1471-0528.13254","article-title":"Validation of an obstetric comorbidity index in an external population","volume":"122","author":"Metcalfe","year":"2015","journal-title":"BJOG"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"237.e1","DOI":"10.1016\/j.ajog.2008.06.028","article-title":"Diabetes mellitus and birth defects","volume":"199","author":"Correa","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/EDE.0000000000000163","article-title":"Estimating the proportion of all observed birth defects occurring in pregnancies terminated by a second-trimester abortion","volume":"25","author":"Svensson","year":"2014","journal-title":"Epidemiology"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M15-3016","article-title":"Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes","volume":"164","author":"Chamberlain","year":"2016","journal-title":"Ann Intern Med"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"337.e1","DOI":"10.1016\/j.ajog.2014.09.031","article-title":"Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study","volume":"212","author":"Bateman","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1007\/s00246-015-1182-9","article-title":"Maternal hypertension during pregnancy and the risk of congenital heart defects in offspring: a systematic review and meta-analysis","volume":"36","author":"Ramakrishnan","year":"2015","journal-title":"Pediatr Cardiol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201701000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T15:11:04Z","timestamp":1689088264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201701000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001775","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}